MétaCan
Menu
← Back to cohort

FGFR1 overexpression and anti-FGFR compound sensitivity in renal cell carcinoma.

2014· article· en· W2908462842 on OpenAlexaff
Ilya Tsimafeyeu, Е. В. Степанова, Elina Zaveleva, Marat Gordiyev, Nigel Wynn

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsPonatinibMedicineRenal cell carcinomaFibroblast growth factor receptor 1CancerImmunohistochemistryCancer researchInternal medicinePathologyFibroblast growth factorReceptorDasatinib

Abstract

fetched live from OpenAlex

e15544 Background: Fibroblast growth factor receptor 1 (FGFR1) plays a significant role in renal cell carcinoma (RCC) pathogenesis. There are several compounds targeting FGFR1 on the horizon. Here, we report changes in FGFR1 overexpression/mutation and anti-FGFR compound sensitivity in RCC. Methods: Twenty-eight female NCr nu/nu mice (6-12 weeks of age) were used for xenotransplantation of human clear cell renal carcinoma Caki-1 cell line. Mice with established FGFR1-expressing tumors (an average size of 80-120 mg) received intravenous OM-RCA-01 (humanized anti-FGFR1 monoclonal antibody, 10 mg/kg, twice a week; N=14) or oral ponatinib (pan-FGFR inhibitor, 30 mg/kg, daily; N=14). Tumor sizes were measured in a blind fashion twice a week with a vernier caliper. Additionally, primary tumor and metastatic lesion of 40 RCC patients were accessed. Animal and patient formalin-fixed, paraffin-embedded specimens of tumors were evaluated by immunohistochemistry with FGFR1 antibodies. FGFR1 mutations were assessed by PCR and direct sequencing. Results: At in vivo study termination day (Day 31), there were 6 (43%) and 5 (36%) tumors reached end-point volume of 2000 mm3 in OM-RCA-01 and ponatinib groups, respectively. Nine (82%) of these 11 resistant tumors had no FGFR1 expression (5 and 4 tumors in OM-RCA-01 and ponatinib groups). FGFR1 was highly expressed in all 17 tumors that responded to OM-RCA-01 or ponatinib. Intensity was 3+ in all cases. Expression of FGFR1 was observed in 92.5% (37/40) of primary tumors and in 65% (26/40) of metastasis in RCC patients. FGFR1 expression decreased in 32% (12/37) and increased in 67% (2/3) of metastasis in comparison with primary tumors. No FGFR1 mutations were detected in animal and patient tumors. Conclusions: FGFR1 overexpression could be different in primary RCC and metastasis of same patient. Expression of FGFR1 was found in 100% of renal tumors that responded to anti-FGFR therapy and in 18% of resistant RCC. Further translational studies will provide more information.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.088
GPT teacher head0.404
Teacher spread0.316 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicRenal cell carcinoma treatment→French-language works237,207→